Literature DB >> 8986721

Sequential involvement of Lck and SHP-1 with MHC-recognizing receptors on NK cells inhibits FcR-initiated tyrosine kinase activation.

B A Binstadt1, K M Brumbaugh, C J Dick, A M Scharenberg, B L Williams, M Colonna, L L Lanier, J P Kinet, R T Abraham, P J Leibson.   

Abstract

Recognition of major histocompatibility (MHC) class I complexes on target cells by killer cell inhibitory receptors (KIR) blocks natural killer (NK) and T cell cytotoxic function. The inhibitory effect of KIR ligation requires the phosphotyrosine-dependent association of KIR with the cytoplasmic SH2-containing protein tyrosine phosphatase SHP-1. Using a somatic genetic model, we first define a requirement for the Src family protein tyrosine kinase (PTK) Lck in mediating KIR tyrosine phosphorylation. We then investigate how KIR ligation interrupts PTK-dependent NK cell activation signals. Specifically, we show that KIR ligation inhibits the Fc receptor (FcR)-induced tyrosine phosphorylation of the FcR-associated zeta signaling chain, the PTK ZAP-70, and phospholipase C gamma. Overexpression of catalytically inactive SHP-1 (acting as a dominant negative) restores the tyrosine phosphorylation of these signaling events and reverses KIR-mediated inhibition of NK cell cytotoxic function. These results suggest sequential roles for Lck and SHP-1 in the inhibition of PTK following MHC recognition by NK cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8986721     DOI: 10.1016/s1074-7613(00)80276-9

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  75 in total

1.  Ly49A inhibitory receptors redistribute on natural killer cells during target cell interaction.

Authors:  M Eriksson; J C Ryan; M C Nakamura; C L Sentman
Journal:  Immunology       Date:  1999-06       Impact factor: 7.397

2.  H-2Dd engagement of Ly49A leads directly to Ly49A phosphorylation and recruitment of SHP1.

Authors:  M R Daws; M Eriksson; L Oberg; A Ullén; C L Sentman
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

3.  Alloreactivity and association of human natural killer cells with the major histocompatibility complex.

Authors:  E Mavoungou; A Sall; V Poaty-Mavoungou; F S Toure; P Yaba; A Delicat; J Lansoud-Soukate
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

Review 4.  ITAMs versus ITIMs: striking a balance during cell regulation.

Authors:  Daniel D Billadeau; Paul J Leibson
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

Review 5.  Role of adhesion molecules in activation signaling in T lymphocytes.

Authors:  M L Dustin
Journal:  J Clin Immunol       Date:  2001-07       Impact factor: 8.317

Review 6.  Innate self recognition by an invariant, rearranged T-cell receptor and its immune consequences.

Authors:  Aleksandar K Stanic; Jang-June Park; Sebastian Joyce
Journal:  Immunology       Date:  2003-06       Impact factor: 7.397

7.  Vav1 dephosphorylation by the tyrosine phosphatase SHP-1 as a mechanism for inhibition of cellular cytotoxicity.

Authors:  Christopher C Stebbins; Carsten Watzl; Daniel D Billadeau; Paul J Leibson; Deborah N Burshtyn; Eric O Long
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

8.  Finding Balance: T cell Regulatory Receptor Expression during Aging.

Authors:  Mary M Cavanagh; Qian Qi; Cornelia M Weyand; Jörg J Goronzy
Journal:  Aging Dis       Date:  2011-10-28       Impact factor: 6.745

Review 9.  Combination strategies to enhance antitumor ADCC.

Authors:  Holbrook E Kohrt; Roch Houot; Aurélien Marabelle; Hearn Jay Cho; Keren Osman; Matthew Goldstein; Ronald Levy; Joshua Brody
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

10.  Dedicator of cytokinesis 8 interacts with talin and Wiskott-Aldrich syndrome protein to regulate NK cell cytotoxicity.

Authors:  Hyoungjun Ham; Sabrice Guerrier; JungJin Kim; Renee A Schoon; Erik L Anderson; Michael J Hamann; Zhenkun Lou; Daniel D Billadeau
Journal:  J Immunol       Date:  2013-03-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.